These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 28397129)

  • 1. The Evolving Evidence for Therapeutic Drug Monitoring of Monoclonal Antibodies in Inflammatory Bowel Disease.
    Sheasgreen C; Nguyen GC
    Curr Gastroenterol Rep; 2017 May; 19(5):19. PubMed ID: 28397129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
    Carman N; Mack DR; Benchimol EI
    Curr Gastroenterol Rep; 2018 Apr; 20(5):18. PubMed ID: 29623442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
    Warman A; Straathof JW; Derijks LJ
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug monitoring of biologics in inflammatory bowel disease.
    Eser A; Primas C; Reinisch W
    Curr Opin Gastroenterol; 2013 Jul; 29(4):391-6. PubMed ID: 23703367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease.
    Mitrev N; Leong RW
    Expert Opin Drug Saf; 2017 Mar; 16(3):303-317. PubMed ID: 27922765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel Disease.
    Restellini S; Khanna R; Afif W
    Inflamm Bowel Dis; 2018 Sep; 24(10):2165-2172. PubMed ID: 29788272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease.
    Franca R; Curci D; Lucafò M; Decorti G; Stocco G
    Expert Opin Drug Metab Toxicol; 2019 Jul; 15(7):527-539. PubMed ID: 31177858
    [No Abstract]   [Full Text] [Related]  

  • 8. Review article: Optimisation of biologic (monoclonal antibody) therapeutic response in inflammatory bowel disease.
    Chaemsupaphan T; Leong RW; Vande Casteele N; Seow CH
    Aliment Pharmacol Ther; 2024 Nov; 60(9):1234-1243. PubMed ID: 39403056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience.
    Mitchell RA; Shuster C; Shahidi N; Galorport C; DeMarco ML; Rosenfeld G; Enns RA; Bressler B
    Can J Gastroenterol Hepatol; 2016; 2016():5203898. PubMed ID: 27957480
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology.
    Papamichael K; Cheifetz AS
    Curr Opin Rheumatol; 2020 Jul; 32(4):371-379. PubMed ID: 32412995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
    Papamichael K; Cheifetz AS; Melmed GY; Irving PM; Vande Casteele N; Kozuch PL; Raffals LE; Baidoo L; Bressler B; Devlin SM; Jones J; Kaplan GG; Sparrow MP; Velayos FS; Ullman T; Siegel CA
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1655-1668.e3. PubMed ID: 30928454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proactive Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease.
    Roblin X; Riviere P; Flamant M; Veyrard P; Poullenot F; Paul S; Laharie D
    Inflamm Bowel Dis; 2018 Aug; 24(9):1904-1909. PubMed ID: 29726958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease: An Answer to Optimized Treatment?
    Hoseyni H; Xu Y; Zhou H
    J Clin Pharmacol; 2018 Jul; 58(7):864-876. PubMed ID: 29462502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.
    Mitrev N; Vande Casteele N; Seow CH; Andrews JM; Connor SJ; Moore GT; Barclay M; Begun J; Bryant R; Chan W; Corte C; Ghaly S; Lemberg DA; Kariyawasam V; Lewindon P; Martin J; Mountifield R; Radford-Smith G; Slobodian P; Sparrow M; Toong C; van Langenberg D; Ward MG; Leong RW;
    Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1037-1053. PubMed ID: 29027257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Zealand Society of Gastroenterology Guidelines on Therapeutic Drug Monitoring in Inflammatory Bowel Disease.
    Khan A; Berahmana AB; Day AS; Barclay ML; Schultz M
    N Z Med J; 2019 Mar; 132(1491):46-62. PubMed ID: 30845128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.
    Khanna R; Sattin BD; Afif W; Benchimol EI; Bernard EJ; Bitton A; Bressler B; Fedorak RN; Ghosh S; Greenberg GR; Marshall JK; Panaccione R; Seidman EG; Silverberg MS; Steinhart AH; Sy R; Van Assche G; Walters TD; Sandborn WJ; Feagan BG
    Aliment Pharmacol Ther; 2013 Sep; 38(5):447-59. PubMed ID: 23848220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease.
    Fernandes SR; Bernardo S; Simões C; Gonçalves AR; Valente A; Baldaia C; Moura Santos P; Correia LA; Tato Marinho R
    Inflamm Bowel Dis; 2020 Jan; 26(2):263-270. PubMed ID: 31247074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases.
    Vande Casteele N; Herfarth H; Katz J; Falck-Ytter Y; Singh S
    Gastroenterology; 2017 Sep; 153(3):835-857.e6. PubMed ID: 28774547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases.
    Kantasiripitak W; Wang Z; Spriet I; Ferrante M; Dreesen E
    Expert Rev Clin Pharmacol; 2021 Dec; 14(12):1455-1466. PubMed ID: 35034509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.